For research use only. Not for therapeutic Use.
SK609（Cat No.:I036338）is a small molecule inhibitor developed for its potential therapeutic applications in cancer treatment. It primarily targets the kinesin spindle protein (KSP), a motor protein essential for proper cell division, especially during mitosis. By inhibiting KSP, SK609 disrupts the mitotic process, leading to cell cycle arrest and subsequent cancer cell death. This makes it a promising candidate for treating a variety of cancers, including solid tumors. Preclinical studies have shown its potent anticancer activity, and SK609 is currently being evaluated in clinical trials for its safety, efficacy, and pharmacokinetic profile.
| Catalog Number | I036338 |
| CAS Number | 144887-95-6 |
| Synonyms | SK-609; SK 609; SK609 |
| Molecular Formula | C10H15Cl2N |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 4-(2-chlorophenyl)butan-2-amine |
| InChI | InChI=1S/C10H14ClN/c1-8(12)6-7-9-4-2-3-5-10(9)11/h2-5,8H,6-7,12H2,1H3 |
| InChIKey | JPYONMJJWKTSBP-UHFFFAOYSA-N |
| SMILES | CC(CCC1=CC=CC=C1Cl)N |
| Reference | 1: Xu W, Wang X, Tocker AM, Huang P, Reith ME, Liu-Chen LY, Smith AB 3rd, Kortagere S. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists. ACS Chem Neurosci. 2017 Mar 15;8(3):486-500. doi: 10.1021/acschemneuro.6b00221. Epub 2016 Nov 23. PubMed PMID: 27801563; PubMed Central PMCID: PMC5813806. |
